BioLife Solutions financials
$39.22+0.18%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5M | $27.5M | $18.8M | $28.1M | $23.4M | $22.1M | $15.1M | $21.4M | $19.7M | $18.4M | $32.7M | $23.6M |
| Gross profit | $18.3M | $17.5M | $12.0M | $17.9M | $15.2M | $14.8M | $10.7M | $14.0M | $13.2M | $12.2M | $9.3M | $12.0M |
| Gross margin | 64.2% | 63.6% | 63.8% | 63.9% | 65.0% | 67.1% | 70.5% | 65.4% | 67.0% | 66.4% | 28.3% | 50.9% |
| Operating income | $1.7M | $27.0K | $1.3M | -$89.0K | -$16.1M | -$499.0K | $542.0K | -$418.0K | -$1.3M | -$3.3M | -$13.2M | -$15.5M |
| Net income | $45.1M | $1.2M | $11.1M | $621.0K | -$15.8M | -$448.0K | $12.5M | -$1.7M | -$20.7M | -$10.2M | -$13.4M | -$29.1M |
| Net margin | 158.4% | 4.3% | 58.9% | 2.2% | −67.6% | −2.0% | 82.5% | −8.0% | −105.1% | −55.4% | −40.9% | −123.6% |
| Diluted EPS | $0.91 | $0.02 | $0.22 | $0.01 | $-0.33 | $0.00 | $0.27 | $-0.04 | $-0.45 | $-0.22 | $-0.30 | $-0.67 |
| EBITDA | $2.5M | $726.0K | $1.9M | $1.2M | -$14.7M | $885.0K | $2.2M | $1.9M | $1.1M | -$1.0M | -$13.6M | -$5.5M |
| Operating cash flow | $6.3M | -$491.0K | $4.9M | $6.1M | $7.4M | $1.7M | $1.6M | $4.8M | $6.5M | -$4.5M | $2.3M | -$4.6M |
| Free cash flow | $5.3M | -$658.0K | -$228.0K | $2.8M | $5.2M | $1.6M | -$1.2M | $3.7M | $5.9M | -$5.3M | -$73.0K | -$7.0M |
| Diluted shares | 49.3M | 49.2M | 49.7M | 48.7M | 47.8M | 48.4M | 46.7M | 46.2M | 46.0M | 45.4M | 44.8M | 43.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.0M | $22.8M | $33.0M | $29.5M | $31.9M | $66.9M |
| Short-term investments | $58.4M | $58.2M | $55.9M | $49.5M | $49.9M | $21.6M |
| Total debt | $0.00 | $2.5M | $5.0M | $7.5M | $10.1M | $12.9M |
| Total assets | $447.5M | $400.9M | $405.9M | $392.1M | $387.2M | $395.1M |
| Total liabilities | $27.5M | $28.7M | $34.0M | $38.3M | $40.1M | $42.5M |
| Shareholders' equity | $420.0M | $372.2M | $371.9M | $353.7M | $347.2M | $352.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology